Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Profile

Martin Cannon

Concepts (305)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Dendritic Cells
27
2025
133
4.330
 Why?
Ovarian Neoplasms
24
2025
459
4.160
 Why?
Immunotherapy
15
2026
266
2.810
 Why?
Cancer Vaccines
13
2020
79
2.770
 Why?
Th17 Cells
3
2020
26
1.390
 Why?
Oncolytic Virotherapy
3
2026
28
1.340
 Why?
Antigens, Neoplasm
11
2019
146
1.240
 Why?
Myxoma virus
2
2025
15
1.110
 Why?
CD4-Positive T-Lymphocytes
8
2023
166
0.990
 Why?
Oncolytic Viruses
1
2025
13
0.920
 Why?
Uterine Cervical Neoplasms
13
2011
301
0.880
 Why?
Oncogene Proteins, Viral
7
2011
52
0.750
 Why?
Neoplasm Recurrence, Local
3
2020
647
0.710
 Why?
T-Lymphocytes, Regulatory
6
2011
83
0.670
 Why?
T-Lymphocytes, Cytotoxic
12
2013
67
0.650
 Why?
Lymphocytes, Tumor-Infiltrating
5
2025
89
0.620
 Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
3
2014
14
0.610
 Why?
CD8-Positive T-Lymphocytes
12
2025
145
0.570
 Why?
Neoplasms
4
2019
1334
0.520
 Why?
Antibodies, Monoclonal
5
2019
477
0.520
 Why?
DNA-Binding Proteins
5
2007
423
0.510
 Why?
Cell Line, Tumor
16
2026
1470
0.500
 Why?
Interleukin-17
2
2020
34
0.500
 Why?
Adjuvants, Immunologic
4
2025
52
0.480
 Why?
p38 Mitogen-Activated Protein Kinases
2
2014
92
0.480
 Why?
Tumor Microenvironment
4
2026
274
0.480
 Why?
Female
44
2026
28782
0.440
 Why?
T-Lymphocytes
5
2017
321
0.420
 Why?
Ascites
1
2014
31
0.420
 Why?
Immunologic Surveillance
2
2011
10
0.410
 Why?
Humans
56
2026
53230
0.390
 Why?
Cytokines
4
2014
627
0.370
 Why?
Carcinoma
2
2017
136
0.370
 Why?
Signal Transduction
3
2017
1748
0.370
 Why?
Animals
19
2026
13526
0.360
 Why?
T-Lymphocytes, Helper-Inducer
2
2011
39
0.350
 Why?
Immunotherapy, Active
1
2011
4
0.350
 Why?
Carcinoma, Hepatocellular
2
2025
212
0.350
 Why?
Serine Endopeptidases
3
2009
50
0.350
 Why?
Cytotoxicity, Immunologic
7
2011
55
0.340
 Why?
Mice
12
2026
5982
0.320
 Why?
Liver Neoplasms
2
2025
346
0.320
 Why?
Adoptive Transfer
1
2009
29
0.300
 Why?
Immunotherapy, Adoptive
3
2005
163
0.290
 Why?
Interferon-gamma
7
2020
174
0.280
 Why?
Epitopes, T-Lymphocyte
3
2008
25
0.270
 Why?
Lymphocyte Activation
3
2005
163
0.260
 Why?
Papillomavirus Vaccines
1
2007
74
0.250
 Why?
Herpesvirus 4, Human
2
2005
44
0.250
 Why?
Immunodominant Epitopes
2
2008
9
0.250
 Why?
Isoantigens
1
2026
15
0.240
 Why?
Carcinoma, Pancreatic Ductal
1
2026
43
0.240
 Why?
Dependovirus
3
2011
104
0.220
 Why?
Virus Replication
1
2025
149
0.210
 Why?
HLA-A2 Antigen
3
2009
11
0.210
 Why?
Pancreatic Neoplasms
1
2026
219
0.200
 Why?
Cell Transformation, Viral
1
2003
25
0.200
 Why?
Cell Line, Transformed
1
2003
73
0.200
 Why?
Poxviridae Infections
1
2022
4
0.190
 Why?
Programmed Cell Death 1 Receptor
2
2025
46
0.190
 Why?
Poxviridae
1
2022
7
0.190
 Why?
Interferon Type I
1
2022
28
0.190
 Why?
Cystadenocarcinoma, Serous
5
2009
73
0.180
 Why?
Vaccination
4
2010
310
0.180
 Why?
Disease-Free Survival
2
2020
466
0.180
 Why?
Papillomavirus E7 Proteins
5
2011
30
0.180
 Why?
Interleukin-10
2
2017
81
0.180
 Why?
Receptor, erbB-2
4
2008
79
0.180
 Why?
Genes, MHC Class I
3
2008
11
0.180
 Why?
Flow Cytometry
8
2013
400
0.170
 Why?
Membrane Proteins
4
2011
333
0.170
 Why?
Injections, Intradermal
1
2020
13
0.170
 Why?
Testis
2
2011
74
0.170
 Why?
Macrophages
4
2022
380
0.170
 Why?
Immunity, Humoral
1
2020
23
0.160
 Why?
Coculture Techniques
3
2014
146
0.160
 Why?
Folate Receptor 1
1
2020
27
0.160
 Why?
Cell Movement
2
2019
279
0.160
 Why?
Enzyme-Linked Immunosorbent Assay
2
2013
233
0.160
 Why?
Carcinoma, Lewis Lung
1
2019
10
0.150
 Why?
B-Lymphocytes
5
2017
178
0.150
 Why?
Repressor Proteins
3
2011
149
0.150
 Why?
Melanoma, Experimental
1
2019
34
0.150
 Why?
Self Tolerance
1
2019
1
0.150
 Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2019
1
0.150
 Why?
Transplantation, Autologous
1
2020
488
0.140
 Why?
Aged
12
2020
10429
0.140
 Why?
Cells, Cultured
6
2014
1569
0.140
 Why?
Cytotoxicity Tests, Immunologic
4
2005
26
0.140
 Why?
Mice, Inbred C57BL
4
2025
1925
0.130
 Why?
N-Acetylglucosaminyltransferases
1
2017
14
0.130
 Why?
Receptors, Notch
1
2017
28
0.130
 Why?
HLA Antigens
4
2006
55
0.130
 Why?
Middle Aged
16
2020
13419
0.130
 Why?
Human Umbilical Vein Endothelial Cells
2
2014
102
0.130
 Why?
Neoplastic Stem Cells
1
2017
90
0.130
 Why?
Carcinoma, Papillary
3
2005
50
0.120
 Why?
Genetic Vectors
3
2011
127
0.110
 Why?
Poliovirus Vaccine, Oral
2
2005
4
0.110
 Why?
Poliovirus
2
2005
10
0.110
 Why?
Neoplasm Proteins
1
2017
330
0.110
 Why?
Clinical Trials, Phase I as Topic
1
2015
24
0.110
 Why?
Adenocarcinoma
3
2004
405
0.110
 Why?
Adult
15
2011
14534
0.110
 Why?
Galectin 3
1
2014
13
0.110
 Why?
Antigen Presentation
5
2009
25
0.110
 Why?
Kallikreins
2
2005
19
0.110
 Why?
Neoplasm Invasiveness
3
2017
281
0.110
 Why?
Cystadenocarcinoma, Papillary
2
2005
14
0.100
 Why?
Histocompatibility Antigens Class I
2
2005
47
0.100
 Why?
Peptide Fragments
4
2009
209
0.100
 Why?
Endometrial Neoplasms
2
2005
143
0.100
 Why?
Uterine Neoplasms
2
2005
57
0.100
 Why?
Papillomavirus Infections
3
2011
177
0.100
 Why?
Mutation
1
2019
1337
0.100
 Why?
Intracellular Signaling Peptides and Proteins
2
2022
136
0.090
 Why?
Lymphocytes
1
2013
146
0.090
 Why?
Antigens, Viral
3
2007
44
0.090
 Why?
Killer Cells, Natural
4
2005
113
0.090
 Why?
V-Set Domain-Containing T-Cell Activation Inhibitor 1
1
2011
4
0.090
 Why?
Clonal Anergy
1
2011
13
0.090
 Why?
rho GTP-Binding Proteins
1
2011
11
0.090
 Why?
Disease Models, Animal
3
2025
1517
0.090
 Why?
A Kinase Anchor Proteins
1
2011
3
0.090
 Why?
Calmodulin-Binding Proteins
1
2011
10
0.090
 Why?
Antigen-Presenting Cells
1
2011
22
0.090
 Why?
Antigens, Surface
1
2011
37
0.090
 Why?
Human papillomavirus 16
1
2011
44
0.090
 Why?
Antineoplastic Agents, Alkylating
1
2011
78
0.090
 Why?
Immunity, Cellular
2
2008
64
0.080
 Why?
Uterine Cervical Dysplasia
1
2011
51
0.080
 Why?
Drug Resistance, Neoplasm
5
2017
350
0.080
 Why?
Cyclophosphamide
1
2011
178
0.080
 Why?
Prostate
1
2011
118
0.080
 Why?
Imidazoles
1
2011
114
0.080
 Why?
Diphosphonates
1
2011
92
0.080
 Why?
Gene Expression Regulation, Neoplastic
4
2011
868
0.080
 Why?
Papillomaviridae
3
2005
104
0.080
 Why?
Phenotype
1
2013
803
0.080
 Why?
Neoplasm Staging
3
2007
774
0.080
 Why?
Gene Expression Profiling
2
2005
1112
0.080
 Why?
K562 Cells
2
2008
42
0.080
 Why?
Carrier Proteins
1
2011
315
0.070
 Why?
CA-125 Antigen
1
2008
16
0.070
 Why?
Immediate-Early Proteins
1
2008
18
0.070
 Why?
Green Fluorescent Proteins
1
2008
85
0.070
 Why?
RNA, Messenger
4
2005
1133
0.070
 Why?
Cytomegalovirus
1
2008
42
0.070
 Why?
Interleukin-4
2
2005
40
0.070
 Why?
Antibody Formation
1
2007
49
0.070
 Why?
Prostatic Neoplasms
1
2011
401
0.070
 Why?
Antibodies, Viral
1
2007
109
0.070
 Why?
Amino Acid Sequence
2
2005
563
0.060
 Why?
RNA Interference
2
2017
181
0.060
 Why?
Molecular Sequence Data
2
2005
759
0.060
 Why?
Ovary
3
2017
103
0.060
 Why?
Oligonucleotide Array Sequence Analysis
2
2005
412
0.060
 Why?
Recombinant Proteins
1
2007
489
0.060
 Why?
Hypersensitivity, Delayed
1
2005
18
0.060
 Why?
Breast Neoplasms
3
2003
1222
0.060
 Why?
Monocytes
2
2022
126
0.060
 Why?
CTLA-4 Antigen
1
2025
32
0.060
 Why?
Neoplasms, Squamous Cell
1
2005
7
0.060
 Why?
Cell Line
4
2010
1016
0.060
 Why?
Electroporation
1
2005
18
0.060
 Why?
Poliomyelitis
1
2005
5
0.060
 Why?
Enterotoxins
1
2005
12
0.060
 Why?
Gene Transfer Techniques
1
2005
44
0.060
 Why?
Reverse Transcriptase Polymerase Chain Reaction
4
2008
579
0.060
 Why?
Interleukin-12
1
2005
26
0.060
 Why?
Genes, erbB-2
1
2005
8
0.060
 Why?
Immunologic Memory
1
2005
31
0.060
 Why?
Antigens, Heterophile
1
2005
1
0.060
 Why?
Burkitt Lymphoma
1
2005
27
0.060
 Why?
Plasmodium falciparum
1
2005
26
0.060
 Why?
Endemic Diseases
1
2005
26
0.060
 Why?
Epstein-Barr Virus Infections
1
2005
32
0.060
 Why?
Malaria, Falciparum
1
2005
24
0.050
 Why?
Gangliosides
1
2004
4
0.050
 Why?
Ascitic Fluid
1
2004
13
0.050
 Why?
Proteins
2
2005
351
0.050
 Why?
Genetic Therapy
1
2005
127
0.050
 Why?
Ovariectomy
1
2004
114
0.050
 Why?
Vaccines, Subunit
1
2004
15
0.050
 Why?
Hysterectomy
1
2004
91
0.050
 Why?
Immunization, Passive
1
2004
28
0.050
 Why?
Interleukin-6
1
2005
272
0.050
 Why?
Clinical Trials as Topic
2
2007
466
0.050
 Why?
Tumor Necrosis Factor-alpha
2
2019
392
0.050
 Why?
Cell Differentiation
2
2004
681
0.050
 Why?
Protein Binding
1
2005
670
0.050
 Why?
Epithelial Cells
1
2005
218
0.050
 Why?
Vesiculovirus
1
2022
6
0.050
 Why?
Virus Latency
1
2003
53
0.050
 Why?
Vaccinia virus
1
2022
6
0.050
 Why?
Host Specificity
1
2022
5
0.050
 Why?
Cell Adhesion Molecules
1
2003
88
0.050
 Why?
Cell Communication
1
2003
73
0.050
 Why?
Nucleotidyltransferases
1
2022
16
0.050
 Why?
Mammals
1
2022
58
0.050
 Why?
Tumor Cells, Cultured
4
2003
441
0.050
 Why?
Xenograft Model Antitumor Assays
2
2017
228
0.050
 Why?
Radiotherapy
1
2002
126
0.040
 Why?
Rabbits
1
2022
372
0.040
 Why?
Down-Regulation
1
2003
344
0.040
 Why?
Blood Transfusion
1
2002
127
0.040
 Why?
Disease Progression
2
2019
880
0.040
 Why?
Viral Proteins
1
2022
164
0.040
 Why?
Immunohistochemistry
4
2005
975
0.040
 Why?
Carcinoma, Squamous Cell
1
2004
332
0.040
 Why?
Endothelium
1
2019
38
0.040
 Why?
Transcriptome
1
2022
367
0.040
 Why?
Intercellular Adhesion Molecule-1
1
2019
59
0.040
 Why?
Gene Expression
3
2008
618
0.040
 Why?
Antineoplastic Combined Chemotherapy Protocols
1
2004
1043
0.040
 Why?
Injections, Intraperitoneal
2
2010
55
0.030
 Why?
Tissue Banks
1
2017
9
0.030
 Why?
Mice, Inbred NOD
1
2017
90
0.030
 Why?
Antibodies, Monoclonal, Humanized
3
2004
238
0.030
 Why?
STAT3 Transcription Factor
1
2017
89
0.030
 Why?
Glycosylation
1
2017
104
0.030
 Why?
Tumor Burden
1
2017
132
0.030
 Why?
RNA, Small Interfering
1
2017
214
0.030
 Why?
Multiple Myeloma
1
2011
3082
0.030
 Why?
Protein Processing, Post-Translational
1
2017
149
0.030
 Why?
Kaplan-Meier Estimate
1
2017
487
0.030
 Why?
Lung Neoplasms
1
2002
645
0.030
 Why?
Survival Analysis
2
2010
659
0.030
 Why?
Apoptosis
2
2014
1139
0.030
 Why?
Perforin
2
2005
12
0.030
 Why?
Pore Forming Cytotoxic Proteins
2
2005
11
0.030
 Why?
Neovascularization, Pathologic
1
2014
158
0.030
 Why?
Anti-Bacterial Agents
1
2019
830
0.020
 Why?
Interleukin-2
2
2003
69
0.020
 Why?
Membrane Glycoproteins
2
2005
238
0.020
 Why?
Vaginal Smears
1
2011
28
0.020
 Why?
Organ Specificity
1
2011
115
0.020
 Why?
Prostate-Specific Antigen
1
2011
43
0.020
 Why?
DNA, Viral
1
2011
136
0.020
 Why?
Time Factors
2
2010
2991
0.020
 Why?
Major Histocompatibility Complex
1
2010
13
0.020
 Why?
Prognosis
2
2005
2118
0.020
 Why?
Transduction, Genetic
1
2008
44
0.020
 Why?
Fluorescent Antibody Technique
1
2008
109
0.020
 Why?
Leukocytes, Mononuclear
1
2008
122
0.020
 Why?
Alphapapillomavirus
1
2007
14
0.020
 Why?
T-Lymphocyte Subsets
1
2007
39
0.020
 Why?
Models, Immunological
1
2007
8
0.020
 Why?
Aged, 80 and over
2
2005
3494
0.020
 Why?
Immune Tolerance
1
2007
91
0.020
 Why?
HLA-B Antigens
1
2006
8
0.020
 Why?
Adolescent
2
2011
6907
0.020
 Why?
Clone Cells
1
2006
76
0.020
 Why?
Immunity, Innate
1
2007
112
0.020
 Why?
Combined Modality Therapy
1
2007
640
0.010
 Why?
Male
3
2011
27435
0.010
 Why?
Claudin-3
1
2005
5
0.010
 Why?
Claudin-4
1
2005
7
0.010
 Why?
Mice, Inbred C3H
1
2005
81
0.010
 Why?
Protein Sorting Signals
1
2005
7
0.010
 Why?
Peptides
1
2006
234
0.010
 Why?
Protein Engineering
1
2005
18
0.010
 Why?
Histocompatibility Antigens Class II
1
2005
35
0.010
 Why?
Mice, SCID
1
2005
180
0.010
 Why?
Plasmids
1
2005
164
0.010
 Why?
Species Specificity
1
2005
191
0.010
 Why?
Protein Folding
1
2005
60
0.010
 Why?
Epithelium
1
2004
64
0.010
 Why?
Endocytosis
1
2005
47
0.010
 Why?
Receptors, Cell Surface
1
2005
109
0.010
 Why?
Carboplatin
1
2004
57
0.010
 Why?
Radiotherapy, Adjuvant
1
2004
65
0.010
 Why?
Polymerase Chain Reaction
1
2005
452
0.010
 Why?
Transfection
1
2005
359
0.010
 Why?
Paclitaxel
1
2004
91
0.010
 Why?
Antineoplastic Agents, Hormonal
1
2004
56
0.010
 Why?
Antibody-Dependent Cell Cytotoxicity
1
2003
12
0.010
 Why?
Tumor Stem Cell Assay
1
2003
16
0.010
 Why?
Proportional Hazards Models
1
2005
445
0.010
 Why?
Cervix Uteri
1
2004
43
0.010
 Why?
Up-Regulation
1
2005
456
0.010
 Why?
Kinetics
1
2005
607
0.010
 Why?
Swine
1
2005
440
0.010
 Why?
Keratinocytes
1
2004
91
0.010
 Why?
Receptors, Interleukin-2
1
2002
6
0.010
 Why?
Lymphocyte Subsets
1
2002
14
0.010
 Why?
Cell Culture Techniques
1
2003
99
0.010
 Why?
Leukocytes
1
2003
58
0.010
 Why?
Receptors, Antigen, T-Cell
1
2003
52
0.010
 Why?
Antigens, CD19
1
2002
29
0.010
 Why?
Cell Death
1
2003
171
0.010
 Why?
Receptors, IgG
1
2002
23
0.010
 Why?
Doxorubicin
1
2004
247
0.010
 Why?
Cisplatin
1
2004
282
0.010
 Why?
Immunophenotyping
1
2002
118
0.010
 Why?
Survival Rate
1
2005
949
0.010
 Why?
Tumor Virus Infections
1
2002
46
0.010
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2002
46
0.010
 Why?
Fatal Outcome
1
2002
193
0.010
 Why?
Cell Division
1
2002
289
0.010
 Why?
Young Adult
1
2011
4511
0.010
 Why?
Case-Control Studies
1
2004
1212
0.010
 Why?
Prospective Studies
1
2004
2411
0.010
 Why?
Risk Factors
1
2004
4017
0.010
 Why?
Antineoplastic Agents
1
2002
1232
0.010
 Why?
Cannon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (305) concept(s)
_
Co-Authors Expand Description
See all (22) people
_
Similar People Expand Description
See all (36) people
_
Same Department Expand Description
Search Department